218 related articles for article (PubMed ID: 17547976)
61. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units.
Cohen BL; Barboglio P; Rodriguez D; Gousse AE
Neurourol Urodyn; 2009; 28(3):205-8. PubMed ID: 19058190
[TBL] [Abstract][Full Text] [Related]
62. [Do psychological factors change in patients with spasmodic dysphonia after injections with botulinum-toxin?].
Kiese-Himmel C; Reeh M; Liebeck H; Zwirner P
Laryngorhinootologie; 2002 Oct; 81(10):683-9. PubMed ID: 12397516
[TBL] [Abstract][Full Text] [Related]
63. Botulinum toxin in the treatment of adductor spasmodic dysphonia.
Thompson AR
J Ark Med Soc; 1994 Jan; 90(8):383-5. PubMed ID: 8175618
[TBL] [Abstract][Full Text] [Related]
64. [The application of botulinum toxin type A in the treatment of spastic paraparesis].
Sobolewski P
Przegl Lek; 2007; 64 Suppl 2():3-7. PubMed ID: 17953270
[TBL] [Abstract][Full Text] [Related]
65. Botulinum toxin-a in children with congenital spastic hemiplegia does not improve upper extremity motor-related function over rehabilitation alone: a randomized controlled trial.
Rameckers EA; Speth LA; Duysens J; Vles JS; Smits-Engelsman BC
Neurorehabil Neural Repair; 2009; 23(3):218-25. PubMed ID: 19106252
[TBL] [Abstract][Full Text] [Related]
66. Toward improved differential diagnosis of adductor spasmodic dysphonia and muscle tension dysphonia.
Roy N; Mauszycki SC; Merrill RM; Gouse M; Smith ME
Folia Phoniatr Logop; 2007; 59(2):83-90. PubMed ID: 17337898
[TBL] [Abstract][Full Text] [Related]
67. Repeated botulinum toxin injections can improve mobility in patients with spinal cord lesions.
Catz A; Barkol H; Steinberg F; Ronen J; Bluvshtein V; Keren O
Eura Medicophys; 2007 Sep; 43(3):319-25. PubMed ID: 17525702
[TBL] [Abstract][Full Text] [Related]
68. Use of botulinum toxin in voice restoration after laryngectomy.
Khemani S; Govender R; Arora A; O'Flynn PE; Vaz FM
J Laryngol Otol; 2009 Dec; 123(12):1308-13. PubMed ID: 19607736
[TBL] [Abstract][Full Text] [Related]
69. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.
Hsiung GY; Das SK; Ranawaya R; Lafontaine AL; Suchowersky O
Mov Disord; 2002 Nov; 17(6):1288-93. PubMed ID: 12465070
[TBL] [Abstract][Full Text] [Related]
70. Factors Associated with Failure of Botulinum Toxin Injection in Adductor Spasmodic Dysphonia.
Zhao K; Guillaud M; Hu A
Ann Otol Rhinol Laryngol; 2020 Oct; 129(10):996-1002. PubMed ID: 32468829
[TBL] [Abstract][Full Text] [Related]
71. [The efficacy of botulinum toxin-A in the treatment of hypersalivation in children with cerebral palsy].
Alataş N; Yazgan P; Oztürk A; San I
Kulak Burun Bogaz Ihtis Derg; 2006; 16(2):49-53. PubMed ID: 16763416
[TBL] [Abstract][Full Text] [Related]
72. Effects of botulinum toxin on vocal tract steadiness in patients with spasmodic dysphonia.
Zwirner P; Murry T; Woodson GE
Eur Arch Otorhinolaryngol; 1997; 254(8):391-5. PubMed ID: 9332896
[TBL] [Abstract][Full Text] [Related]
73. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes.
Novakovic D; Waters HH; D'Elia JB; Blitzer A
Laryngoscope; 2011 Mar; 121(3):606-12. PubMed ID: 21298641
[TBL] [Abstract][Full Text] [Related]
74. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients.
Mascarenhas F; Cocuzza M; Gomes CM; Leão N
Neurourol Urodyn; 2008; 27(4):311-4. PubMed ID: 17914742
[TBL] [Abstract][Full Text] [Related]
75. Eyebrow height after botulinum toxin type A to the glabella.
Carruthers A; Carruthers J
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S26-31. PubMed ID: 17241411
[TBL] [Abstract][Full Text] [Related]
76. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?
Carruthers A; Carruthers J; Cohen J
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S97-104. PubMed ID: 17241422
[TBL] [Abstract][Full Text] [Related]
77. Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?
Nóbrega AC; Rodrigues B; Torres AC; Enzo A; Melo A
J Neurol Sci; 2007 Feb; 253(1-2):85-7. PubMed ID: 17229441
[TBL] [Abstract][Full Text] [Related]
78. Speech intelligibility in severe adductor spasmodic dysphonia.
Bender BK; Cannito MP; Murry T; Woodson GE
J Speech Lang Hear Res; 2004 Feb; 47(1):21-32. PubMed ID: 15072525
[TBL] [Abstract][Full Text] [Related]
79. Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury.
Hori S; Patki P; Attar KH; Ismail S; Vasconcelos JC; Shah PJ
BJU Int; 2009 Jul; 104(2):216-20. PubMed ID: 19220255
[TBL] [Abstract][Full Text] [Related]
80. Contraindications and complications with the use of botulinum toxin.
Klein AW
Clin Dermatol; 2004; 22(1):66-75. PubMed ID: 15158548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
